GB2569615A — An oral liquid pharmaceutical composition of lamotrigine`
Assigned to Syri Ltd · Expires 2019-06-26 · 7y expired
What this patent protects
An oral liquid pharmaceutical composition comprising lamotrigine present in the range from about 1 mg/ml to 25 mg/ml, a suspending agent, a sweetener, at least one preservative and one or more inactive excipients, wherein the ratio of lamotrigine to suspending agent is 1:0.1 to 1…
USPTO Abstract
An oral liquid pharmaceutical composition comprising lamotrigine present in the range from about 1 mg/ml to 25 mg/ml, a suspending agent, a sweetener, at least one preservative and one or more inactive excipients, wherein the ratio of lamotrigine to suspending agent is 1:0.1 to 1:10 is provided. Preferably the pH of the composition is in the range from about 5 to 8. The suspending agent is preferably selected from xanthan gum, guar gum, tragacanth gum, veegum, HPMC (hydroxypropyl methylcellulose), microcrystalline cellulose, sodium carboxymethyl cellulose, carboxylvinyl polymer, polyvinyl pyrrolidone or combinations thereof. An oral liquid pharmaceutical composition comprising (a) 5mg/ml of lamotrigine, (b) a suspending agent selected from carboxyvinyl polymers and combination of microcrystalline cellulose with carboxymethyl cellulose sodium, (c) a sweetener selected from acesulfame potassium, sucralose, cyclamate, saccharin, saccharin sodium and aspartame, and (d) at least one preservative and one or more inactive excipients is provided.
Drugs covered by this patent
- Lipitor (Atorvastatin Calcium) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.